VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones

VOLITIONRX LTD

Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.
Cash and equivalents $10.0M at March 31, 2023 vs $10.9M at year-end 2022.
Received ~$8M net from Feb public offering; expects $13M in Heska milestone payments and additional non-dilutive Belgian funding.
Launched Nu.Q Vet Cancer Test through IDEXX and Heska; planning more country launches in 2023.
Advancing Nu.Q NETs test for sepsis with multi-site U.S. studies and FDA Breakthrough Device application.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VOLITIONRX LTD reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the first quarter ended March 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-23-003238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.